Therapy for pneumonitis and sialadenitis by accumulation of CCR2-expressing CD4+CD25+ regulatory T cells in MRL/lpr mice

被引:21
|
作者
Hasegawa, Hitoshi
Inoue, Atsushi
Muraoka, Masatake
Yamanouchi, Jun
Miyazaki, Tatsuhiko
Yasukawa, Masaki
机构
[1] Ehime Univ, Sch Med, Dept Internal Med 1, Div Pathogenom, Toon, Ehime 7910295, Japan
[2] Ehime Univ, Sch Med, Dept Pathol, Div Pathogenom, Toon, Ehime 7910295, Japan
关键词
D O I
10.1186/ar2122
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Adoptive transfer of CD4+ CD25+ regulatory T cells has been shown to have therapeutic effects in animal models of autoimmune diseases. Chemokines play an important role in the development of autoimmune diseases in animal models and humans. The present study was performed to investigate whether the progression of organ-specific autoimmune diseases could be reduced more markedly by accumulating chemokine receptor-expressing CD4+ CD25+ regulatory T cells efficiently in target organs in MRL/MpJ-lpr/lpr (MRL/lpr) mice. CD4+ CD25+ Foxp3+ T cells (Treg cells) and CD4+ CD25+ Foxp3+ CCR2-transfected T cells (CCR2-Treg cells) were transferred via retro-orbital injection into 12-week-old MRL/lpr mice at the early stage of pneumonitis and sialadenitis, and the pathological changes were evaluated. Expression of monocyte chemoattractant protein-1 (MCP-1)/ CCL2 was observed in the lung and submandibular gland of the mice and increased age-dependently. The level of CCR2 expression and MCP-1 chemotactic activity of CCR2-Treg cells were much higher than those of Treg cells. MRL/lpr mice to which CCR2-Treg cells had been transferred showed significantly reduced progression of pneumonitis and sialadenitis in comparison with MRL/lpr mice that had received Treg cells. This was due to more pronounced migration of CCR2-Treg cells and their localization for a longer time in MCP1- expressing lung and submandibular gland, resulting in stronger suppressive activity. We prepared chemokine receptor-expressing Treg cells and demonstrated their ability to ameliorate disease progression by accumulating in target organs. This method may provide a new therapeutic approach for organ-specific autoimmune diseases in which the target antigens remain undefined.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] The role of CD4+CD25+ regulatory T cells in viral infections
    Vahlenkamp, TW
    Tompkins, MB
    Tompkins, WAF
    VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 2005, 108 (1-2) : 219 - 225
  • [42] Prevention of autoimmune disease by CD4+CD25+ regulatory T cells
    Van Driel, IR
    Zwar, TD
    Allen, S
    Read, S
    Gleeson, PA
    TISSUE ANTIGENS, 2005, 66 (05): : 574 - 575
  • [43] The effects of antibody treatment on regulatory CD4+CD25+ T cells
    Yi, Huanfa
    Zhang, Jialin
    Zhao, Yong
    TRANSPLANT IMMUNOLOGY, 2008, 19 (01) : 37 - 44
  • [44] CD4+CD25+ regulatory T cells in human lupus erythematosus
    Annegret Kuhn
    Stefan Beissert
    Peter H. Krammer
    Archives of Dermatological Research, 2009, 301 : 71 - 81
  • [45] CD4+CD25+ regulatory T cells in human lupus erythematosus
    Kuhn, Annegret
    Beissert, Stefan
    Krammer, Peter H.
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 2009, 301 (01) : 71 - 81
  • [46] CD4+CD25+ regulatory T cells in rheumatoid arthritis.
    van Amelsfort, JMR
    Jacobs, KMG
    Bijlsma, JWJ
    Lafeber, FPJ
    Taams, LS
    ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S486 - S486
  • [47] Signal transduction in CD4+CD25+ regulatory T cells:: CD25 and IL-2
    Thornton, AM
    FRONTIERS IN BIOSCIENCE, 2006, 11 : 921 - 927
  • [48] Analysis of the interaction of CD4+CD25+ regulatory T cells with dendritic cells
    Herman, S.
    Bonelli, M.
    Von Dalwigk, K.
    Smolen, J. S.
    Scheinecker, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : A6 - A6
  • [49] CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2
    Antony, PA
    Restifo, NP
    JOURNAL OF IMMUNOTHERAPY, 2005, 28 (02) : 120 - 128
  • [50] Accumulation of CD4+CD25+ regulatory T cells in the CNS during recovery from EAE.
    McGeachy, MJ
    Stephens, LA
    Anderton, SM
    CLINICAL IMMUNOLOGY, 2005, 115 : S89 - S89